Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis

Jason J. Song,1,2 Inyong Hwang,1,2 Kyung H. Cho,2 Michael A. Garcia,1,2 Arthur J. Kim,1,2 Tiffany H. Wang,1,2 Tamsin M. Lindstrom,1,2 Annette T. Lee,3 Toshihiko Nishimura,4 Lei Zhao,5 John Morser,6 Michael Nesheim,8 Stuart B. Goodman,7 David M. Lee,8 S. Louis Bridges Jr.,9 for the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry, Peter K. Gregersen,3 Lawrence L. Leung,2,9 and William H. Robinson1,2

The immune and coagulation systems are both implicated in the pathogenesis of rheumatoid arthritis (RA). Plasma carboxypeptidase B (CPB), which is activated by the thrombin/thrombomodulin complex, plays a procoagulant role during fibrin clot formation. However, an antiinflammatory role for CPB is suggested by the recent observation that CPB can cleave proinflammatory mediators, such as C5a, bradykinin, and osteopontin. Here, we show that CPB plays a central role in downregulating C5a-mediated inflammatory responses in autoimmune arthritis. CPB deficiency exacerbated inflammatory arthritis in a mouse model of RA, and cleavage of C5a by CPB suppressed the ability of C5a to recruit immune cells in vivo. In human patients with RA, genotyping of nonsynonymous SNPs in the CPB-encoding gene revealed that the allele encoding a CPB variant with a longer half-life was associated with a lower risk of developing radiographically severe RA. Functionally, this CPB variant was more effective at abrogating the proinflammatory properties of C5a. Additionally, expression of both CPB and C5a in synovial fluid was higher in patients with RA than in those with osteoarthritis. These findings suggest that CPB plays a critical role in dampening local, C5a-mediated inflammation and represents a molecular link between inflammation and coagulation in autoimmune arthritis.

Introduction

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by activation of both inflammatory and coagulation pathways (1). Fibrin deposition, the culmination of the coagulation cascade, is a hallmark of RA synovium (2, 3). Deposited fibrin can promote inflammatory responses (4), while citrulline-modified fibrin(ogen) is a prominent target of RA-specific autoantibodies (5). In animal models of arthritis, inhibition of thrombin or fibrin reduces the severity of arthritis (4, 6). Clinically, the incidence of coronary artery disease (CAD) is increased in the RA population, and antiinflammatory therapy reduces CAD-associated mortality in RA patients (7, 8). However, the molecular links between inflammation and coagulation have not been well characterized.

Thrombin-activatable plasma carboxypeptidase B (CPB), also known as activated thrombin-activatable fibrinolysis inhibitor [TAFIa] or carboxypeptidase U) is a component of the coagulation pathway that protects blood clots from fibrinolysis (9). It is produced mainly by the liver as a zymogen (proCPB) and is also detected in platelets (10). Activation of CPB occurs during thrombotic events (11), through the removal of a so-called activation peptide in the N terminus of proCPB (9). Although thrombin and plasmin can activate proCPB in vitro by cleaving the activation peptide, the thrombin cofactor thrombomodulin (TM) accelerates the rate of CPB activation approximately 1,000-fold by forming a thrombin/TM complex, which is considered the physiological activator of proCPB (12).

By removing C-terminal lysine residues exposed on partially degraded fibrin, CPB decreases the binding of plasminogen and tissue plasminogen activator to fibrin, thereby suppressing the generation of the fibrinolytic enzyme plasmin (13). Recently, several proinflammatory mediators, such as C5a, osteopontin (OPN), and bradykinin, have been identified as substrates of CPB in vitro (14, 15). Therefore, by cleaving fibrin lysines and thereby maintaining fibrin clots, CPB may serve a procoagulant and proinflammatory function. Alternatively, by suppressing the activity of the proinflammatory mediators C5a, OPN, and bradykinin, CPB may serve an antiinflammatory function. Illustrating this duality of function, CPB deficiency was protective in a model of glomerulonephritis (16), whereas it increased lethality in a model of hepatitis (17). CPB could therefore play several contrasting roles in autoimmune arthritis. To investigate the role of CPB in autoimmune arthritis, we analyzed biological samples derived from patients with RA, as well as mice deficient in CPB or in substrates of CPB. In addition, we performed genotyping to determine whether non-

Authorship note: Michael Nesheim is deceased.
Conflict of interest: David M. Lee is currently employed by Novartis Pharma AG.

Citation for this article: J Clin Invest. 2011;121(9):3517–3527. doi:10.1172/JCI46387.

The Journal of Clinical Investigation http://www.jci.org Volume 121 Number 9 September 2011 3517
synonymous SNPs in CPB2 are associated with human RA. Our findings indicate that CPB plays a protective role in autoimmune arthritis by cleaving C5a and thereby suppressing inflammatory cell migration and activation.

Results

**CPB protects against anti-collagen antibody–induced arthritis.** To investigate the role of CPB in inflammatory arthritis, we generated anti-collagen antibody-induced arthritis (CAIA) in mice lacking Cpb2. At 7–10 days after injection with the anti-collagen antibodies, Cpb2−/− mice exhibited more severe arthritis than Cpb2+/+ mice (Figure 1A). Histologic analysis of joint sections revealed greater erosive damage, synovial hyperplasia, and inflammatory cell infiltration in Cpb2−/− compared with Cpb2+/+ mice (Figure 1B and C). These findings demonstrate that CPB protects against the development of inflammatory arthritis. To assess the gene-dose effect of Cpb2, we compared the severity of CAIA in Cpb2−/−, Cpb2+/−, and Cpb2+/+ mice and found that Cpb2 heterozygosity was sufficient to protect against the severe CAIA seen in Cpb2−/− mice (Figure 1D).

**Deficiency in C5, but not OPN or bradykinin receptor B2, protects against CAIA.** To determine which of CPB’s substrates is involved in CAIA, we induced CAIA in C5-deficient mice, OPN-deficient (Spp1−/−) mice, and bradykinin B2 receptor–deficient (Bdkrb2−/−) mice. We chose Bdkrb2−/− over Bdkrb1−/− mice because the B2 receptor binds uncleaved bradykinin with greater affinity than CPB-cleaved bradykinin, whereas the B1 receptor preferentially binds CPB-cleaved bradykinin (18). In contrast to the experiments presented in Figure 1, in which a suboptimal dose of anti-collagen antibodies was used to induce arthritis, an optimal dose of anti-collagen antibodies was delivered for experiments involving CPB substrate-deficient mice. Compared with controls, C5-deficient mice were resistant to CAIA (Figure 2A), consistent with a previous report (19). In contrast, there was no difference in arthritis severity between Spp1−/− or Bdkrb2−/− mice and their respective controls (Figure 2A).
Inhibition of plasmin with tranexamic acid aggravates CAIA in CPB-deficient mice. By cleaving the C-terminal lysine residues exposed on partially degraded fibrin, CPB decreases the binding of plasminogen to fibrin, thereby suppressing the generation of plasmin (13). Thus, plasmin generation in response to fibrin deposition is heightened in Cpb2–/– mice (20). Plasmin could contribute to the pathogenesis of arthritis by promoting cartilage degradation, either by directly cleaving cartilage proteoglycans or by activating MMPs (21). To determine whether an increase in plasmin levels accounts for the exacerbation of arthritis in Cpb2–/– mice, we induced CAIA in Cpb2–/– mice and treated them with tranexamic acid (TA), which blocks plasmin generation. TA treatment did not reverse, but instead accentuated, the exacerbation of CAIA in Cpb2–/– mice (26). Furthermore, the C5-deficient mice received 4 mg of anti-collagen antibodies, whereas the Cpb2–/– mice received only 2 mg of anti-collagen antibodies. It is possible that differences in genetic background, the lower dose of anti-collagen antibodies, and/or possible off-target effects of the anti-C5 antibody BB5.1 could be responsible for the great extent to which arthritis severity was reduced in Cpb2–/– mice treated with BB5.1 (Figure 2C).

CPB regulates inflammatory cell migration by cleaving C5a. To further explore the interaction between CPB and C5a, we examined the effect of CPB-mediated cleavage on the chemotactic properties of C5a in vivo. Because it is difficult to obtain sufficient mouse synovial fluid for cellular analyses, we initially assessed C5a’s ability to recruit inflammatory cells to the mouse peritoneal cavity. We incubated recombinant C5a with CPB in order to generate the CPB-cleaved form of C5a (C5a-desArg; lacking the C-terminal arginine) and confirmed removal of the C-terminal arginine by mass spectrometry (Figure 3A). We then injected C5a that had been treated or not treated with CPB into the peritoneal cavity of wild-type mice, and 5 hours later harvested peritoneal fluid for flow cytometric analysis. There were fewer neutrophils in peritoneal fluid from mice administered CPB-treated C5a than from those administered PBS-treated C5a (Figure 3B). CPB-treated C5a also induced less synovial inflammation than did PBS-treated C5a when injected...
into the stifle (knee) joints of mice (Figure 3C). Furthermore, using the Zymosan A–induced (ZyA-induced) peritonitis model, in which inflammatory cells are recruited to the peritoneum in a C5a-dependent manner (27), we found that neutrophil and macrophage recruitment was greater in Cpb2−/− than in Cpb2+/+ mice (Figure 3D). These data suggest that CPB is antiinflammatory by cleaving C5a, thus inactivating C5a’s chemotactic properties.

**CPB SNP 1040T encoding the long half-life Ile325 CPB protects against radiographic progression of RA.** We next performed genotyping to determine whether polymorphisms in the CPB2 gene are associated with human RA. Previously, 2 nonsynonymous SNPs have been reported in the coding region of CPB2: rs3742264 (G505A encoding Ala147Thr) and rs1926447 (C1040T encoding Thr325Ile) (28, 29). Only the C1040T SNP has known functional consequences, with Ile325 CPB having a 2-fold longer half-life and being more effective at inhibiting fibrinolysis than Thr325 CPB (30). We genotyped the 2 nonsynonymous CPB2 SNPs in an African American RA cohort (the Consortium for the Longitudinal Evaluations of
African Americans with Early Rheumatoid Arthritis [CLEAR] Registry) and in age- and gender-matched healthy individuals. Using our genotyping data, we first asked whether the C1040T SNP (rs1926447) is associated with susceptibility to RA; we found no significant association (Table 1). We next asked whether the C1040T SNP is associated with RA severity, as assessed by radiography of hands and feet and quantified by the modified Sharp/van der Heijde score (SHS) (31). For this analysis, we used data from SHS were available (for rs1926447, T; for rs3742264, A) alleles, respectively, for each SNP.

Table 1

<table>
<thead>
<tr>
<th>Nonsynonymous CPB2 SNP case-control analysis</th>
<th>rs1926447 (C1040T)</th>
<th>rs3742264 (G505A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size, cases/controls</td>
<td>771/805</td>
<td>778/803</td>
</tr>
<tr>
<td>Genotype, cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>598</td>
<td>271</td>
</tr>
<tr>
<td>AB</td>
<td>157</td>
<td>391</td>
</tr>
<tr>
<td>BB</td>
<td>16</td>
<td>116</td>
</tr>
<tr>
<td>Genotype, controls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>599</td>
<td>301</td>
</tr>
<tr>
<td>AB</td>
<td>186</td>
<td>380</td>
</tr>
<tr>
<td>BB</td>
<td>20</td>
<td>122</td>
</tr>
<tr>
<td>Minor allele frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cases</td>
<td>0.12</td>
<td>0.40</td>
</tr>
<tr>
<td>Controls</td>
<td>0.14</td>
<td>0.39</td>
</tr>
<tr>
<td>Allelic χ², P</td>
<td>0.14</td>
<td>0.50</td>
</tr>
<tr>
<td>Genotype association, AA vs. AB+BB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odds ratio</td>
<td>0.84</td>
<td>1.12</td>
</tr>
<tr>
<td>95% confidence interval</td>
<td>0.67–1.06</td>
<td>0.91–1.38</td>
</tr>
<tr>
<td>χ²</td>
<td>2.14</td>
<td>1.20</td>
</tr>
<tr>
<td>P</td>
<td>0.14</td>
<td>0.27</td>
</tr>
</tbody>
</table>

Sample size refers to the number of samples successfully genotyped. A and B denote the major (for rs1926447, C; for rs3742264, G) and minor (for rs1926447, T; for rs3742264, A) alleles, respectively, for each SNP.

Ile325 CPB is more effective than Thr325 CPB at neutralizing C5a. To gain insight into the mechanism underlying the genotype association, we compared the ability of the CPB variants encoded by the C1040T SNP to inactivate C5a. We incubated C5a with Thr325 CPB (encoded by 1040C) or Ile325 CPB (encoded by 1040T) and used mass spectrometry to measure the generation of C5a-desArg. By evaluating the ratio of C5a-desArg to intact C5a, we found that the long half-life Ile325 CPB cleaved C5a to a greater extent than the short half-life Thr325 CPB (Figure 5A). Furthermore, after 1 hour, C5a treated with Ile325 CPB retained only 21% of its activity, as assessed by its ability to induce neutrophil myeloperoxidase (MPO) release, whereas C5a treated with Thr325 CPB retained as much as 69% of its activity (Figure 5B). Thus, the long half-life Ile325 CPB is 3 times as effective as the short half-life Thr325 CPB at neutralizing the proinflammatory mediator C5a, a difference that may provide the molecular basis for the protective effect of the CPB2 1040T allele on radiographic severity in RA.

CPB levels are elevated in RA synovial fluid and correlate with C5a levels. We next measured C5a and CPB protein levels in synovial fluid and plasma from RA patients. Total CPB levels were higher in RA compared with osteoarthritis (OA) synovial fluid samples (Figure 6B), consistent with a previous report (33). Total C5a levels were also higher in RA compared with OA synovial fluid samples, and synovial fluid CPB levels correlated with C5a levels (Figure 6B). Our data, demonstrating an antiinflammatory role for CPB in murine inflammatory arthritis, suggest that the increase in CPB expression in RA occurs as part of an antiinflammatory feedback mechanism. Data regarding the levels of CPB in the plasma of RA patients are conflicting (34, 35). Although CPB is produced mainly by the liver, we did not observe any differences in plasma CPB levels between RA patients and healthy individuals (Figure 6A), which suggests that the increase in CPB levels in synovial fluid in RA is caused by local production of CPB.

CPB is locally expressed in RA joints. Immunohistochemical analysis showed that CPB protein was present in RA synovial tissues in an interstitial pattern as well as an intracellular pattern (Figure 7). To determine whether CPB is produced locally in the synovial joints in RA, we examined CPB2 mRNA expression in synovial tissue and cells from synovial fluid. Although we recently showed that cultured fibroblast-like synoviocytes (FLSs) can produce CPB (15), assessment of CPB2 expression in situ revealed CPB2 mRNA expression in cells from RA synovial fluid and in RA synovial tissues (Figure 8A). Because inflammatory cells in synovial fluid derive from blood, we assessed CPB2 expression in cells obtained from peripheral blood. Peripheral blood cells and macrophages did the short half-life Thr325 CPB (Figure 5A). Furthermore, after 1 hour, C5a treated with Ile325 CPB retained only 21% of its activity, as assessed by its ability to induce neutrophil myeloperoxidase (MPO) release, whereas C5a treated with Thr325 CPB retained as much as 69% of its activity (Figure 5B). Thus, the long half-life Ile325 CPB is 3 times as effective as the short half-life Thr325 CPB at neutralizing the proinflammatory mediator C5a, a difference that may provide the molecular basis for the protective effect of the CPB2 1040T allele on radiographic severity in RA.

Figure 4

RA patients who possess the CPB2 1040T allele, encoding long half-life CPB, have a lower risk of progressing to radiographically severe RA. RA patients in the CLEAR I cohort (n = 118) who developed radiographically severe RA within 3 years (1040C homozygotes, 13%; 1040T carriers, 39%; 1040T carriers, 13%; P = 0.026, χ² test). In contrast, the G505A (rs3742264) genotype was not associated with radiographic severity.
differentiated in vitro expressed CPB (Figure 8B). The macrophage differentiation factor M-CSF, which is highly expressed in RA synovial fluids (36), increased CPB2 expression in the monocyte cell line U937 (Figure 8C). In addition, dexamethasone, a potent antiinflammatory agent, increased CPB mRNA and CPB protein expression in U937 cells (Figure 8, C and D). Thus, local production by synovial inflammatory cells and synoviocytes may account for the increase in CPB levels in RA joints.

**Discussion**

Several components of the coagulation pathway are involved in inflammation (37). For example, the procoagulant fibrin is proinflammatory by promoting the migration and activation of inflammatory cells and the production of proinflammatory cytokines (38), whereas the anticoagulant protein C is antiinflammatory by promoting the cytoprotective pathways that inhibit apoptosis or cytokine productions (39). CPB possesses both antifibrinolytic activity (and thus potentially proinflammatory activity) and antiinflammatory activity, and its role in inflammatory arthritis has not been characterized. In this study, we demonstrated that CPB protected against inflammatory arthritis in mice, exerting an antiinflammatory effect by inactivating the anaphylatoxin C5a. Our results with TA suggest that this effect is not mediated by the fibrin-plasmin pathway. Our findings in mice translated to human RA, in which carriage of the CPB2 1040T allele (encoding the long half-life Ile325 CPB) protected against erosive damage of RA joints. Furthermore, we found that the long half-life Ile325 CPB neutralized C5a activity more efficiently than its short half-life counterpart, a difference that may underlie the protection conferred by the CPB2 1040T allele. Together, our findings suggest that CPB is a molecular link between inflammation and coagulation in RA. Activated during coagulation, CPB dampens inflammation in the synovial joints and ultimately reduces joint damage in RA.

The RA joint provides an environment suitable for activation of CPB. In RA synovial fluid, molecular markers of thrombin activation (thrombin-anti-thrombin III complexes and thrombin fragments) are significantly elevated (33). In addition, TM levels are increased in RA synovial fluids, and TM is expressed in RA joint tissue, mainly in endothelial cells and synovial lining cells (40). By forming the thrombin/TM complex, TM dramatically increases the rate of activation of both protein C and CPB approximately 1,000-fold (12, 41). Although the 2 proteins activated by the thrombin-TM complex are both antiinflammatory, they have opposing effects on coagulation: whereas protein C has anticoagulant activity, CPB has antifibrinolytic activity. Thus, coagulation and inflammation are interlinked processes that are tightly regulated in the RA joint.

Although CPB markedly inhibits fibrinolysis in vitro, CPB-deficient mice have no overt phenotype or coagulation abnormalities (20). Moreover, restoration of antifibrinolytic activity by TA in CPB-deficient mice exacerbated inflammatory arthritis, which suggests that inhibition of fibrinolysis is not the main mechanism by which CPB protects against inflammatory arthritis. Indeed, our mouse data suggest that CPB’s primary role in inflammatory arthritis is an antiinflammatory one. Among CPB’s known proinflammatory substrates, OPN and bradykinin were not important in CAIA. C5a, in contrast, is known to be involved in autoimmune arthritis in humans and mice (42, 43). By cleaving C5a, CPB suppressed immune cell migration, a process important in RA pathogenesis.

Unlike in mice, there is no known case of CPB deficiency in humans. However, our human genomic data are consistent with our mouse phenotypic data showing that Cpb2 provides a protective effect on inflammatory arthritis. RA patients carrying the CPB2 allele encoding long half-life CPB (1040T) were less likely to progress to radiographically severe arthritis. We found that 1 copy of the allele was sufficient to provide protection, consistent with our results from mice heterozygously deficient in CPB. Interestingly, the CPB2 genotype was not associated with disease susceptibility, which suggests that the genetic factors that drive development of RA are distinct from those that drive progression of RA. CPB2 genotyping could potentially be performed in order to screen for the RA risk allele.

**Table 2**

<table>
<thead>
<tr>
<th></th>
<th>CT/TT, n (%)</th>
<th>CC, n (%)</th>
<th>Odds ratio (95% CI)</th>
<th>Relative risk (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe</td>
<td>3 (13.0)</td>
<td>37 (38.9)</td>
<td>0.24 (0.07–0.85)</td>
<td>29.3% (9.2–92.6)</td>
<td>0.026</td>
</tr>
<tr>
<td>Mild</td>
<td>20 (87.0)</td>
<td>58 (61.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Severe and mild were defined as the top tertile and the middle and bottom tertile, respectively, of radiographic severity as measured by modified SHS.

**Table 3**

<table>
<thead>
<tr>
<th></th>
<th>CT/TT</th>
<th>CC</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>55.4 ± 10.6</td>
<td>59.8 ± 13.6</td>
<td>0.095</td>
</tr>
<tr>
<td>Disease duration (months)</td>
<td>103.4 ± 12.8</td>
<td>98.8 ± 16.4</td>
<td>0.148</td>
</tr>
<tr>
<td>Smoking</td>
<td>10 (43.5)</td>
<td>54 (56.8)</td>
<td>0.263</td>
</tr>
<tr>
<td>Anti-CCP positive</td>
<td>15 (65.2)</td>
<td>62 (65.3)</td>
<td>0.798</td>
</tr>
<tr>
<td>RF positive</td>
<td>19 (82.6)</td>
<td>69 (72.6)</td>
<td>0.721</td>
</tr>
<tr>
<td>HLA-DRB1 shared epitope present</td>
<td>11 (47.8)</td>
<td>46 (48.4)</td>
<td>0.960</td>
</tr>
<tr>
<td>CRP, year 0 (mg/l)</td>
<td>9.9 ± 22.5</td>
<td>15.2 ± 33.4</td>
<td>0.374</td>
</tr>
<tr>
<td>Tender joint count (0–38)</td>
<td>7.2 ± 7.3</td>
<td>8.7 ± 8.9</td>
<td>0.409</td>
</tr>
<tr>
<td>Swollen joint count (0–42)</td>
<td>4.9 ± 6.2</td>
<td>4.8 ± 6.4</td>
<td>0.968</td>
</tr>
<tr>
<td>DAS28, year 0</td>
<td>3.7 ± 1.4</td>
<td>4.0 ± 1.4</td>
<td>0.371</td>
</tr>
<tr>
<td>HAQ, year 0</td>
<td>1.7 ± 0.9</td>
<td>1.8 ± 0.9</td>
<td>0.942</td>
</tr>
<tr>
<td>Treatment with DMARDs</td>
<td>21 (91.3)</td>
<td>80 (84.2)</td>
<td>0.323</td>
</tr>
<tr>
<td>SHS, year 0</td>
<td>0.3 ± 0.8</td>
<td>2.3 ± 5.3</td>
<td>0.001</td>
</tr>
<tr>
<td>SHS, year 3</td>
<td>1.8 ± 3.9</td>
<td>5.0 ± 12.0</td>
<td>0.007</td>
</tr>
<tr>
<td>Erosion score, year 0</td>
<td>0.3 ± 0.8</td>
<td>1.0 ± 2.4</td>
<td>0.035</td>
</tr>
<tr>
<td>Erosion score, year 3</td>
<td>0.6 ± 1.1</td>
<td>2.6 ± 6.5</td>
<td>0.005</td>
</tr>
<tr>
<td>JSN score, year 0</td>
<td>0.0 ± 0.0</td>
<td>1.3 ± 3.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>JSN score, year 3</td>
<td>1.2 ± 3.2</td>
<td>3.2 ± 6.3</td>
<td>0.033</td>
</tr>
</tbody>
</table>

Values are mean ± SD or n (%), as applicable. 100% of patients were female. CCP, cyclic citrullinated peptide antibody; RF, rheumatoid factor; DMARD, disease-modifying antirheumatic drug; JSN, joint-space narrowing; HAQ, health assessment questionnaire; CRP, C-reactive protein. HLA-DRB1 shared epitope alleles were *0101, *0102, *0401, *0404, *0405, *0413, *1001, and *1402.
for RA patients who are at risk of progressing to a severe, erosive form of the disease or to predict the response of RA patients to therapeutic inhibitors targeting CPB substrates, such as anti-C5a therapy. Even though the CPB2 1040T allele had a protective effect on RA, it is also associated with an increased risk of certain thrombotic diseases (44–47), which demonstrates the diverse role of CPB in inflammation and coagulation.

Although erosive changes were reduced in patients carrying the CPB2 1040T allele, we observed no differences in other disease activity indices, including DAS28, health assessment questionnaire score, tender joint count, and CRP, between CPB2 1040T allele carriers and 1040C homozygotes. CPB may have a direct role in bone and/or cartilage erosion in addition to its role in inflammation, given that there is evidence that C5a plays a direct role in bone and cartilage erosion by mediating osteoclast activation (48) and by inducing MMP expression by RA FLSs (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI46387DS1). Alternatively, the differences in CPB half-life may not be sufficient to affect inflammatory markers at a single time point, but could potentially dampen chronic inflammatory responses over time and thereby reduce erosive progression.

Multiple genetic factors associated with RA have been discovered during the last decade (49). Understanding their contribution to RA pathogenesis requires evaluation of their biological effects. However, for the vast majority of genetic variants associated with RA, there is no known functional effect of the variants. Here we demonstrated that long half-life CPB had greater C5a-neutralizing capability. Nevertheless, the molecular mechanisms by which the genetic variants of CPB affect RA may extend beyond regulation of inflammation mediated by C5a, because C5 inhibition using a neutralizing antibody provided only a trend toward modest benefit in human RA (50), and C5a-receptor inhibition failed to provide benefit (51). Thus, it remains possible that CPB’s effect in RA is mediated through multiple substrates.

Once activated, CPB has a short half-life of 5–10 minutes at 37°C (52). No physiological inhibitors of CPB have been identified, and inactivation of CPB is achieved only through spontaneous structural destabilization of CPB after release of its activation peptide (53). Therefore, the stability of CPB is an important determinant of its functional activity. In addition, CPB levels are higher in RA synovial fluids than in OA synovial fluids, possibly secondary to chronic inflammation and activation of the coagulation pathway

**Figure 5**
C5a-neutralizing activities of CPB variants. (A) C5a-desArg generation by CPB variants. The ratio of C5a-desArg to intact C5a at each time point was measured by mass spectrometry, the data fit was calculated by 1-phase exponential models, and half-times ($t_{1/2}$; 50% of the time necessary to reach the calculated plateau) of C5a cleavage was determined. The Ile325 CPB variant’s half-time was twice as long as that of Thr325 CPB. (B) C5a neutralization by CPB variants. Ile325 CPB was more efficient than Thr325 CPB at neutralizing C5a activity, as assessed by C5a-mediated induction of neutrophil MPO release. Activity of C5a over time is presented as a percentage of C5a activity at 0 minutes of CPB treatment. *$P < 0.01$, Student’s t test.

**Figure 6**
CPB levels in plasma and synovial fluid of RA patients. (A) Similar levels of CPB were present in plasma derived from RA patients ($n = 10$) and healthy controls ($n = 20$). (B) CPB and total C5a levels were elevated in RA ($n = 20$) compared with OA ($n = 19$) synovial fluid ($*P < 0.05$, **$P < 0.01$, Student’s t test). CPB levels correlated with total C5a levels ($P < 0.01$, Pearson correlation test) in RA and OA synovial fluid.
as part of a compensatory anti-inflammatory mechanism. Therefore, it is highly plausible that differences in the half-life of distinct CPB variants could influence disease progression in RA. CPB levels in plasma, however, did not differ between RA patients and healthy individuals, which suggests that CPB is produced locally in RA. We have previously demonstrated that cultured FLSs express CPB (15), and showed in the present study that immune cells also produced CPB. Local production of CPB might be important in modulating local inflammatory processes.

Together, our findings suggest that CPB, a component of the coagulation system, plays a critical role in downregulating local inflammatory and antifibrinolytic effect, but also an anti-inflammatory one. By cleaving C5a, CPB dampened inflammation in the synovial joints in a mouse model of autoimmune arthritis.

Methods

Mouse studies. Cpb2–/– mice were extensively backcrossed to the C57BL/6 background at the Jackson Laboratory as previously described (26), and C57BL/6 mice or Cpb2+/- littermates were used as controls. C5-deficient mice, Spp1+/– mice, Bdkrb2+/– mice, and controls were purchased from Jackson Laboratory. Mice were housed at Stanford University, and experiments were performed under protocols approved by the Stanford University Committee of Animal Research and in accordance with NIH guidelines. CAIA was induced by tail vein injection of anti-collagen II antibody (Arthrogen-CIA; Chondrex), followed by i.p. injection of 50 μg LPS (Sigma-Aldrich) 3 days later. Mice deficient in CPB substrates and their controls were injected with an optimal dose (4–6 mg/mouse) of anti-collagen antibody to induce severe arthritis in the control groups, so that we could observe a reduction in severity caused by deficiency in a CPB substrate. In contrast, CPB-deficient mice and their controls were injected with a suboptimal dose (2 mg/mouse) of anti-collagen antibody to minimize arthritis in their control groups, so that we could observe an exacerbation of disease in CPB-deficient mice. Mice were scored daily for arthritis by using the visual scoring system and by measuring paw thickness. For the TA studies, mice received 15 mg TA (Pfizer) via subcutaneous injection 1 day before the injection of anti-collagen antibody, and then daily until the conclusion of the study, using previously described protocols (54). Mice were also injected with 40 μg LPS on days 3 and 8. For the anti-C5 antibody studies, mice received 750 μg anti-C5 antibody i.p. (provided by V.M. Holers, University of Colorado, Denver, Colorado, USA) on days 0 and 2 using previously described protocols (23).

Scoring of murine arthritis. Arthritis in mice was scored according to the following visual scoring system, as previously described (55): 0, no swelling or erythema; 1, mild swelling and erythema or digit inflammation; 2, moderate swelling and erythema confined to the region distal to the mid-paw; 3, pronounced swelling and erythema with extension to the ankle; 4, severe swelling, erythema, and joint rigidity of the ankle, foot, and digits. Each limb was graded with a score of 0–4, with a maximum possible score of 16 for each individual mouse. Paw thickness was determined by measuring the thickness of the hind paws with 0–10 mm calipers.

Tissue processing. Joint tissue was harvested, decalcified, and embedded with paraffin. Sections of the paraffin-embedded tissue were stained with H&E and scored by a blinded examiner for inflammatory cell infiltrates, erosion of cartilage or bone, and synovial hyperplasia.

ZyA-induced peritonitis model. Peritoneal inflammation was induced as previously described (56). ZyA (Sigma-Aldrich) was prepared in sterile PBS (2 mg/ml), and 0.5 ml was i.p. injected into mice. At selected time points, animals were euthanized, and peritoneal cells were harvested by lavage with 5 mM EDTA-PBS. Cells were counted with a hemocytometer and stained for granulocytes and macrophages with anti-mouse Gr1 and F4/80 (BD Biosciences). Cells (1 × 10^6 per tube) were incubated with purified Fc block (anti-mouse CD16/CD32; BD Biosciences) for 5 minutes, washed, resuspended in staining buffer, and analyzed using a FACSscalibor flow cytometer (BD Biosciences).

In vitro chemotaxis assay. 120 μM C5a (R&D Systems) was incubated with 70 nM activated CPB (American Diagnostica) in HBSS for 45 minutes at room temperature and for 15 minutes at 37°C. Analysis of full-length C5a (Asn679–Arg755) and CPB-cleaved C5a (Asn679–Gly754) was performed on a PerSeptive Voyager-DE RP Biospectrometry MALDI-TOF mass spectrometer operating in linear mode using delayed extraction under standard conditions at the Stanford Protein and Nucleic Acid Facility. 2.5 μg CPB- or PBS-treated C5a was injected into the mouse peritoneum. 5 hours after injection of C5a, peritoneal cells were harvested and analyzed as described above.

Intra-articular injection of C5a. 5 μl CPB- or PBS-treated C5a (0.5 mg/ml) was injected into the mouse stifle joint using a 29-gauge needle and microsyringe (Hamilton Co.). Stifle joints were harvested and processed for H&E staining 72 hours later.

CLEAR Registry. The CLEAR Registry enrolled self-declared African Americans who were diagnosed with RA. CLEAR I is a longitudinal cohort of early RA (disease duration less than 2 years from time of symptom onset), and CLEAR II is a cross-sectional cohort of RA of any duration (57). Genotyping for CPB2 SNPs rs1926447 and rs3742264 was performed using a custom Illumina Infinium iSelect Genotyping Beadchip on DNA samples from the CLEAR I (n = 337) and CLEAR II (n = 446) registries and from
control healthy individuals (n = 808), as part of the International MHC and Autoimmunity Genetics Network (IMAGEN). For analysis of associations with RA susceptibility, we used genotyping data from a group of 808 healthy African Americans matched for age and gender, approximately 500 recruited as part of the CLEAR Registry and approximately 300 recruited from the Birmingham area (samples provided by R. Kimberly and J. Edberg, University of Alabama at Birmingham, Birmingham, Alabama, USA). For analysis of associations with radiographic severity, we used genotyping data from RA patients in the CLEAR I cohort who were assigned an SHS at the 3-year visit (n = 139). Radiographs of the hands and feet were obtained at baseline and at 3 years, and radiographic damage was quantified using the SHS (31). Clinical data, laboratory data, radiographic data, and CPB2 SNP data were analyzed for female patients only (n = 118), because the relatively small number of men who possess the CPB2 SNP rs1926447 minor allele in the CLEAR I cohort (n = 4) precluded meaningful analysis.

**Effect of CPB variants on C5a cleavage and activity.** Recombinant human Thr325 CPB and Ile325 CPB were expressed in baby hamster kidney cells and purified as described previously (30). Each form of CPB (0.2 μM) protein was activated with thrombin (5 nM), thrombomodulin (20 nM), HEPES (20 mM) and CaCl2 (5 mM) in HBSS at 24°C for 10 minutes, after which the thrombin was quenched with PPACK (1 μM). Recombinant human C5a (1 μM) was then hydrolyzed by each form of activated CPB protein (2 nM) at 37°C. Aliquots were removed at 0, 5, 10, 20, 40, and 60 minutes, and C5a cleavage was stopped by 1 mM EDTA (pH 7.6). To evaluate CPB-mediated cleavage of C5a, we measured levels of C5a and C5a-desArg in each reaction mix using an Exacta (Thermo Fisher Scientific) orbitrap mass spectrometer coupled to a UPLC (Waters) chromatograph equipped with a Poroshell 300SB-C3 75 × 2 mm column (Agilent). Detection was performed in m/z 600–2,000 mass range using electrospray ionization in positive mode. Spectra of multiply charged ions were deconvoluted using ProMass software (Thermo Fisher Scientific). The C5a-desArg/C5a ratio was calculated for each time point. To evaluate CPB-mediated inhibition of C5a activity, we measured the release of MPO from neutrophils incubated with the CPB-treated C5a. Briefly, neutrophils were prepared, according to a published protocol (58), from buffy-coat concentrates obtained from the Stanford Blood Bank. Neutrophils (4 × 106 cells/ml) were resuspended in HBSS with 0.25% bovine serum albumin. 1 ml of neutrophils was treated with 5 μg/ml of cytochalasin B for 5 minutes at 37°C. 1 μl of each reaction mix of CPB-cleaved C5a (as described above) was added to the neutrophil suspension, incubated for 15 minutes at 37°C, and centrifuged. MPO released into the supernatant was measured by a commercial MPO activity assay kit (Invitrogen) at A590, as recommended.

**Human samples.** Human plasma, synovial fluid, and synovial tissue samples were collected from healthy individuals and from RA and OA patients who met American College of Rheumatology criteria. All samples, including samples collected as part of the CLEAR Registry, were obtained and
used under human subjects protocols approved by the Investigational Review Boards at Stanford University and University of Alabama at Birmingham. All samples were collected after informed consent, except for the synovial fluid samples, which were obtained as discarded remnant tissue under an Investigational Review Board-approved protocol that does not require consent.

**ELISA for total CPB, total C5a, and MMP3.** A commercial CPB ELISA kit (Zymutest CPB antigen ELISA kit; Aniara) was used for measurement of CPB protein levels in synovial fluid and plasma. In brief, samples were diluted 1:100. To block nonspecific cross-linking by rheumatoid factor, we preincubated synovial fluid samples with 3 μg/ml of HeteroBlock (Omega Biologicals). 200 μl of samples and the standard CPB solution were used to measure total CPB level, according to the manufacturer’s instructions. Synovial C5a level was measured with a commercial human C5a ELISA kit (BD Biosciences) according to the manufacturer’s instructions. Mouse plasma C5a levels were measured with a commercial mouse C5a ELISA kit (R&D Systems) according to the manufacturer’s instruction. MMP3 levels in FLSs culture supernatants were measured with a commercial MMP3 ELISA kit (R&D Systems) according to the manufacturer’s instructions.

**RA FLS culture.** RA FLSs were isolated from remnant pannus obtained at knee arthroplasty. Pannus was minced; digested at 37°C for 75 minutes with 1 mg/ml collagenase I (Invitrogen), 0.1 mg/ml DNase I (Sigma-Aldrich), and 0.015 mg/ml hyaluronidase (Sigma-Aldrich); and cultured in DMEM, 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin sulfate, and 50 μM 2-mercaptoethanol at 37°C, 8% CO₂, as described previously (55). After the fourth passage, RA FLSs were grown to confluence and stimulated with C5a (2.5 μg/ml; R&D Systems) for 24 hours. RNA was isolated for quantitative PCR, and supernatant was collected for ELISA.

**Cell isolation and culture.** Human pronormocytic U937 cells were obtained from the American Type Culture Collection. Buffo cell concentrates were obtained from the Stanford Blood Bank. Neutrophils and mononuclear cells were isolated by centrifugation at 400 g for 40 minutes with Ficoll-Hypaque. Isolated mononuclear cells (1 x 10⁸) were filtered with a magnetic cell-sorting system (Monocyte Isolation Kit II; Miltenyi Biotec) for the generation of macrophages, isolated monocytes were cultured with 3526 medium containing 1 mg/ml collagenase I (Invitrogen), 0.1 mg/ml DNase I (Sigma-Aldrich), and 0.015 mg/ml hyaluronidase (Sigma-Aldrich); and cultured in DMEM, 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin sulfate, and 50 μM 2-mercaptoethanol at 37°C, 8% CO₂, as described previously (55). After the fourth passage, RA FLSs were grown to confluence and stimulated with C5a (2.5 μg/ml; R&D Systems) for 24 hours. RNA was isolated for quantitative PCR, and supernatant was collected for ELISA.

**RT-PCR and quantitative PCR.** Total RNA was isolated from cells or synovial tissue using Qiagen RNeasy minikit and reverse transcribed into cDNA by using qScript cDNA synthesis kit (Quanta Bioscience). cDNA was amplified by PCR using Top DNA polymerase with universal PCR pre-mix (Bioneer). Primer sequences for standard PCR amplification were as follows: CPB2 forward, 5′-CATGCGAGAAGTTGATGCT-3′; CPB2 reverse, 5′-TCTGGTCTTGGGCTGG-3′; ACTB forward, 5′-TCCCCGTCACCTCCAATCC-3′; MMP3 reverse, 5′-TCCCGGTCACTCCATAATCC-3′; MMP13 forward, 5′-ACTGAGGAGCTCGGAGAAATG-3′; MMP13 reverse, 5′-TGGT-TATCCTGACGGTTGCCCAG-3′.

**Western blotting.** After stimulation with dexamethasone (American Regent), U937 or Huh-7.5 cells were lysed with cell lysis buffer (Mammalian Protein Extraction Reagent; Pierce) containing a protease and phosphatase inhibitor cocktail (Fisher Scientific). Protein lysates were separated by SDS-PAGE, and Western blotting was performed using mouse monoclonal anti-CPB antibody (Haemtagenics Technologies) or mouse monoclonal anti-β-actin antibody (Sigma-Aldrich).

**Immunohistochemistry.** Paraffin-embedded RA synovial tissue sections were prepared through a series of xylene and alcohol rinses and hydration with H₂O. Endogenous peroxidase activity was quenched with 3% H₂O₂ solution (EMD Chemicals), and nonspecific binding blocked with serum-free protein block (Dako). The tissue sections were incubated with rabbit polyclonal anti-CPB antibody (Sigma-Aldrich) or normal rabbit IgG (Santa Cruz) and labeled with Envision+ Rabbit-HRP polymer (Dako). Staining was developed with DAB+ substrate-chromogen solution (Dako), and counterstaining was performed with hematoxylin (Dako).

**Statistics.** Statistical data are presented as mean ± SEM unless otherwise indicated. Statistical differences were assessed by 2-tailed Student’s t test for ELISA data and by Mann-Whitney U test for in vivo experiments. For evaluation of the effect of CPB2 SNPs on disease susceptibility or severity, χ² test was used. For assessment of the correlation between synovial CPB level and C5a level, Pearson correlation test was used.

When multiple comparisons were sought, 1-way ANOVA with appropriate post-hoc tests was used. In all analyses, P values less than 0.05 were considered significant. Statistical analyses were performed using SPSS for Windows, version 16.0 (SPSS), or GraphPad Prism, version 5.1 (GraphPad).

**Acknowledgments**

This work was supported by Department of Veterans Affairs funding, NIH NIAID grant R01-A1085268, NHLBI grant N01-HV00242 Proteomics Center, and ACR Within-Our-Reach funding to W.H. Robinson; NIH NHLBI grant R01-HL057530 to L.L. Leung; ACR physician scientist development award, ACR/AF bridge funding award, and NIH NIAMS grant K08-AR056772 to J.J. Song; grants from the Heart and Stroke Foundation of Ontario to M. Nesheim; and NIH NHLBI grant N01-AR62278, NIH NIAMS grant P60-AR048095, and NIH NCRR grant UL1-RR025777 to S.L. Bridges, Jr. We thank members of the Robinson and Leung laboratories for insightful discussions and technical support; Robert P. Kimberly and Jeffrey C. Edberg for providing approximately 300 African American controls for genotyping; and V. Michael Holers for provision of the anti-C5 antibody BB5.1. We thank CLEAR Registry Investigators Larry W. Moreland (University of Pittsburgh), George Howard (University of Alabama at Birmingham), Doyt L. Conn (Emory University), Beth L. Jonas (University of North Carolina), Leigh F. Callahan (University of North Carolina), Edwin A. Smith (Medical University of South Carolina), and Richard D. Brasington, Jr. (Washington University).

Received for publication January 12, 2011, and accepted in revised form June 1, 2011.
research article


